• 1. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 2. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 3. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 4. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 5. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Trifluoromethylbenzenes
• Solvents and Organic Chemicals Organic Compounds Organic Halides

Recent Advances in the Application of 2-Bromo-1-methyl-4-(trifluoromethyl)benzene (CAS: 66417-30-9) in Chemical Biology and Pharmaceutical Research

2-Bromo-1-methyl-4-(trifluoromethyl)benzene (CAS: 66417-30-9) is a halogenated aromatic compound that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound serves as a key intermediate in the synthesis of various bioactive molecules, including agrochemicals, pharmaceuticals, and materials science applications. The presence of both bromine and trifluoromethyl groups on the benzene ring makes it a valuable building block for further functionalization, enabling the creation of complex molecular architectures with tailored properties.

Recent studies have highlighted the role of 2-Bromo-1-methyl-4-(trifluoromethyl)benzene in the development of novel drug candidates. For instance, researchers have utilized this compound as a precursor in the synthesis of trifluoromethyl-substituted heterocycles, which are known for their enhanced metabolic stability and bioavailability. A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility in constructing potent kinase inhibitors, showcasing its potential in targeted cancer therapies. The study reported a 40% improvement in inhibitory activity compared to non-fluorinated analogs, underscoring the importance of the trifluoromethyl group in drug design.

In addition to its pharmaceutical applications, 2-Bromo-1-methyl-4-(trifluoromethyl)benzene has been employed in materials science, particularly in the development of organic electronic materials. A recent breakthrough published in Advanced Materials (2024) detailed its use as a key intermediate in the synthesis of high-performance organic semiconductors. The researchers attributed the compound's effectiveness to its ability to facilitate π-π stacking interactions, which are crucial for charge transport in electronic devices. This finding opens new avenues for the design of next-generation optoelectronic materials.

The synthetic methodologies involving 66417-30-9 have also seen significant advancements. A 2023 Nature Communications paper reported a novel palladium-catalyzed cross-coupling reaction that enables the efficient incorporation of 2-Bromo-1-methyl-4-(trifluoromethyl)benzene into complex molecular frameworks. This method demonstrated remarkable functional group tolerance and high yields (up to 92%), addressing previous challenges in the compound's derivatization. The authors emphasized the method's potential to accelerate drug discovery pipelines by providing rapid access to diverse chemical space.

From a safety and regulatory perspective, recent toxicological studies have provided valuable insights into the handling and environmental impact of 2-Bromo-1-methyl-4-(trifluoromethyl)benzene. A comprehensive assessment published in Chemical Research in Toxicology (2024) established its acute toxicity profile and recommended appropriate safety measures for industrial-scale applications. These findings are particularly relevant as the compound sees increasing use in Good Manufacturing Practice (GMP) settings for pharmaceutical production.

Looking forward, the unique properties of 2-Bromo-1-methyl-4-(trifluoromethyl)benzene position it as a cornerstone in the development of innovative therapeutic agents and advanced materials. Ongoing research efforts are exploring its potential in emerging areas such as PROTAC (Proteolysis Targeting Chimeras) technology and covalent inhibitor design. The compound's versatility, combined with recent methodological advances, suggests it will remain a focal point in chemical biology and medicinal chemistry research for years to come.

• 392-83-6(2-Bromobenzotrifluoride)
• 261952-20-9(2-Bromo-5-methylbenzotrifluoride)
• 118527-30-3(2-Bromo-1,3-bis(trifluoromethyl)benzene)
• 7657-09-2(2,5-Dibromobenzotrifluoride)
• 327-75-3(1-Bromo-2,4-bis(trifluoromethyl)benzene)
• 1099597-98-4(2-Bromo-1-methyl-3-(trifluoromethyl)benzene)
• 7617-93-8(2-bromo-1,4-bis(trifluoromethyl)benzene)
• 231953-31-4(1,3-Dibromo-2-methyl-5-(trifluoromethyl)benzene)
• 929000-62-4(1-Bromo-2-methyl-4-(trifluoromethyl)benzene)
• 121793-12-2(2-Bromo-4-methyl-1-(trifluoromethyl)benzene)